Skip to main content
Full access
Letter to the Editor
Published Online: 1 July 2005

Sertraline- and Mirtazapine-Induced Severe Neutropenia

Publication: American Journal of Psychiatry
To the Editor: Neutropenia is a rare and reversible side effect of antidepressant treatment (14). Six cases of agranulocytosis in approximately 2 million exposures to mirtazapine have been reported (unpublished data from Organon, Inc., 1999). Because all of the patients had either a concomitant medication or disease that might have been related to agranulocytosis, it has been suggested that the association between mirtazapine and agranulocytosis might have been coincidental (5).
We report on a person with depression who developed severe neutropenia during treatment with mirtazapine and was safely treated with sertraline.
Ms. A, a 44-year-old woman with complaints of sleep disturbance, lack of energy, and unhappiness, was diagnosed with major depressive disorder and administered mirtazapine, 30 mg/day. Her medical history was negative, and the results of routine blood tests (WBC count of 6.8×109/liter) were unremarkable except for a total cholesterol level of 204 mg/dl. Three weeks later, she came in with complaints of a severe sore throat, difficulty swallowing, a loss of appetite, and an aphthous ulcer in her oral mucosa, with a slightly elevated body temperature of 37.7°C during her physical examination. In subsequent blood counts, neutropenia (a WBC count of 2.2×109/liter) was detected, and a blood smear revealed a granulocyte number of 1.1×109/liter. Mirtazapine was immediately discontinued, and sultamicillin, 375 mg b.i.d., was started after consulting with the otorhinolaryngology department. Within 2 weeks, Ms. A’s WBC count and granulocyte count had gradually increased to 3.8×109/liter and 3.2×109/liter, respectively. Four weeks after discontinuation of mirtazapine, sertraline was administered at 50 mg/day. Within 6 weeks, Ms. A’s depression had responded to treatment, with more than a 50% reduction of her score on the Hamilton Depression Rating Scale, while her WBC count was 6.1×109/liter. Upon her final assessment, after 6 months of taking sertraline, her depression had remitted completely, without any adverse effects.
Since there was neither concomitant medication nor medical illness, an association between mirtazapine and severe neutropenia might be suggested. Neutropenia with cross-intolerance between two tricyclics has been described before (6), and there is evidence that patients may successfully be treated with another class of drug after such an incidence (4). Therefore, a selective serotonin reuptake inhibitor, sertraline, was administered and successfully used without an adverse effect. We may hypothesize that a different class of antidepressants might cause agranulocytosis by different mechanisms. Patients should be monitored closely for symptoms indicating agranulocytosis. An antidepressant from a different class might be considered after such an incident.

References

1.
Albertini RS, Penders TM: Agranulocytosis associated with tricyclics. J Clin Psychiatry 1978; 39:483–485
2.
Adams PC, Robinson A, Reid MM, Vishu MC, Livingston M: Blood dyscrasias and mianserin. Postgrad Med J 1983; 59:31–33
3.
Nelson JC: Safety and tolerability of the new antidepressants. J Clin Psychiatry 1997; 58:26–31
4.
Anghelescu I, Klawe C, Dahmen N: Venlafaxine in a patient with idiopathic leukopenia and mirtazapine-induced severe neutropenia (letter). J Clin Psychiatry 2002; 63:838
5.
Davis J, Barkin RL: Clinical pharmacology of mirtazapine: revisited (letter). Am Fam Physician 1999; 60:1101
6.
Draper BM, Manoharan A: Neutropenia with cross-intolerance between two tricyclic antidepressant agents (letter). Med J Aust 1987; 146:452–453

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1386
PubMed: 15994730

History

Published online: 1 July 2005
Published in print: July 2005

Authors

Affiliations

MINE OZMEN, M.D.
Istanbul, Turkey

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share